GW Pharma Receives EU Approval for CBD-Based Epilepsy Drug Epidyolex
We’ve scanned the newsfeeds of all the important marijuana stocks and put together this recap so you don’t have to.
Today was another slow news day for the cannabis sector with the exception of GW Pharma’s (NASDAQ: GWPH) milestone announcement that the company’s CBD-based epilepsy drug Epidyolex received EU approval.
Today’s EU approval will allow GW Pharma to officially commence commercial sales of Epidyolex in all 28 EU countries in addition to Norway, Iceland and Liechtenstein.
Other important news making the rounds today included Friday’s announcement that analyst Bill Kirk of MKM Partners officially initiated coverage on 8 cannabis stocks. The U.S. analyst issued a mixture of bullish/bearish ratings and price targets on the pot stocks.
Here are the rest of the top cannabis stock news stories for Monday, September 23, 2019:
Curaleaf (CSE: CURA) (OTCQX: CURLF) announced the launched of its Curaleaf Ground Flower Pods in New York today.
The company’s MMJ products are the first medical cannabis flower products in the state of New York.
Valens GroWorks (TSXV: VGW) (OTCQX: VGWCF) reported it has received its amended license from Health Canada and updated investors on the progress of the build-out of its white label cannabis manufacturing facility.
“This amended license represents another significant milestone for the company” stated Valens GroWorks CEO Tyler Robson.
Harvest Health (CSE: HARV) (OTCQX: HRVSF) announced today the opening of Harvest of Chandler dispensary.
Today marks the opening of the company’s 11th Harvest Health affiliated dispensary in Arizona.
1933 Industries (CSE: TGIF) (OTCQX: TGIFF) announce that it has started selling its Canna Hemp X CBD recovery cream at specialty retailer Zumiez.
Zumiez is a leading specialty retailer focused on action sports such as skateboarding and snowboarding.
Zenabis Global (TSX: ZENA) (OTCPK: ZBISF) announced it secured its Phase 2C – Part 2 license amendments for the company’s Zenabis Atholville facility.
The new licenses will increase Zenabis’ annual cultivation capacity by 3,000 kg to 57,000 kg.
Cannabix Technologies (CSE: BLO) (OTCPK: BLOZF) announced that it has signed a licensing deal with the University of British Columbia (UBC) to use and commercialize certain cannabis breathalyzer technology.
Cannabis plans to use this technology to offer low-cost portable breathalyzers designed for personal, workplace and parental testing use.
Move Over Curaleaf, There’s a New MSO in Town and it’s Set to Hit The Street This September
Get the full details here so you don’t miss out on the next potential 10 bagger.